Seemingly disappointing survival findings in the final results from the PEARL study are balanced by better quality of life with combination therapy

Significant progression-free survival benefits in pre-treated HER2-positive metastatic disease reported in the DESTINY-BREAST03 and SYD985.002/TULIP trials

Multi-omics approaches incorporating cell-free DNA and circulating tumour DNA show potential in early cancer detection and could help personalise treatment by tumour characteristics

Early-phase studies, COSMIC-021 and CheckMate 9KD, show promising results in men with prostate cancer, but patient selection is key

Too often the access to quality biomarkers is undermined by poor knowledge on the need for quality assurance. Relying on the assumption that biomarkers bring ‘innovation’ without claiming quality may be appealing to some, perhaps not really to medical conservatives – and not to patients, for sure. 

Immunotherapy was associated with a significant reduction in the risk of disease recurrence compared with placebo in patients with melanoma 

Survival benefit with first-line pembrolizumab plus chemotherapy in persistent, recurrent or metastatic cervical cancer

Immune chemo-sensitisation results show potential for this approach in the treatment of advanced CRC, but greater understanding of response characteristics is required in future clinical trials

The oncolytic herpes virotherapy does not show survival benefit in combination with pembrolizumab, but encouraging early data are reported with intratumoural injection of myeloid dendritic cells